Printed and Online Press
On the heels of winning $12 million in supplemental funding from the National Institutes of Health (NIH) to conduct a major, multicenter, national clinical trial of his iLet™ bionic pancreas ...
Beta Bionics shared exclusive breaking news with diaTribe today that it has received an impressive $5 million investment from insulin maker Novo Nordisk in its newest strategic partnership.
That passionate investor base was evident in another of Wefunder’s $1 million campaigns: an experimental medical device for Type 1 diabetes produced by Beta Bionics, a startup headed by Boston University professor Ed Damiano.
Type 1 diabetes does not have a cure. Living with the condition is also time consuming, but science is working to make that treatment a little bit easier.
Patients with type 1 diabetes receiving glucagon from an automatic bionic pancreas experienced fewer symptomatic hypoglycemia episodes compared with those receiving placebo, according to a presenter here.
"Our study found that using automatic glucagon delivery reduced hypoglycemia by 75 percent during the day and 91 percent at night," said lead investigator Courtney Balliro, RN, BS, CDE, Clinical Research Nurse at the MGH Diabetes Research Center, Boston, MA.
Meet Beta Bionics: New Business Structure for iLet Bionic Pancreas
Say hello to Beta Bionics, the new parent company that plans to commercialize the exciting iLet Bionic Pancreas system that administers both insulin and glucagon and was famously developed by researcher and diabetes dad Dr. Ed Damiano at Boston University.
Hope for the Battle against Type 1 Diabetes
Ed Damiano, a Boston University professor of biomedical engineering and the father of a 16-year-old boy with type 1 diabetes, has been racing for nearly 13 years to develop an artificial, or bionic, pancreas that could transform the lives of millions of people who have the same disease as his son, freeing them from the round-the-clock burden of managing a potentially life-threatening disorder themselves.